Selinexor receives Conditional Marketing Authorisation in Europe for the treatment of relapsed and or refractory myeloma patientsAccess, Myeloma30 March 2021
The FDA approves melphalan flufenamide for patients with relapsed or refractory myelomaAccess, Myeloma1 March 2021
Generating recommendations for patient- reported outcome (PRO): SISAQOL-IMIMPE, Patient evidence18 February 2021
Selinexor receives positive opinion from the EMA for the treatment of refractory myelomaAccess, Myeloma30 January 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosis17 January 2021
